SLAB$217.50

Silicon Labs shows a volatile recovery pattern after a steep two-year revenue decline, with FY2025 revenue rebounding 34% and TTM rising modestly above that level. However, profitability remains weak: gross margin has fallen from FY2022’s high but recovered somewhat, while operating margin has stayed negative for three straight years, indicating that top-line gains have not yet translated into durable earnings. Net income improved from FY2024’s deep loss, but TTM remains negative, so the business is still below sustainable profit levels. The income statement does not show clear one-off distortions, though the high TTM tax rate reflects losses. For a semiconductor company, the revenue rebound is encouraging, but expense discipline and margin repair remain key risks.

Silicon Laboratories shows a strong, conservatively structured balance sheet. Liquidity is solid, with TTM cash and short-term investments of $438.9 million, total current assets of $676.3 million, and current liabilities of only $132.5 million, leaving working capital at $543.8 million. Solvency is excellent: total liabilities are just $167.9 million versus $1.10 billion of shareholders’ equity, and total debt has been reduced sharply from $547.6 million in FY2022 to $24.0 million TTM. Equity has remained broadly stable around the $1.1 billion level, although retained earnings have trended lower from prior peaks. The main change is a smaller asset base and lower cash than FY2022, but leverage remains very restrained.

Cash generation has been highly uneven, though FY2025 improved meaningfully: operating cash flow rose to $95.7 million from -$13.9 million in FY2024, while TTM CFO is $52.5 million, below the latest fiscal year. Free cash flow also turned positive at $65.8 million in FY2025 after negative results in FY2023 and FY2024, but TTM FCF has eased to $17.6 million. Capex remained moderate at $29.9 million in FY2025, suggesting reinvestment is controlled. However, working capital swings were material across periods, and the gap between net income and cash flow remains wide. Capital allocation has favored large share repurchases and debt reduction, which looks disciplined but was funded alongside substantial investment sales.

Silicon Laboratories shows very strong short-term liquidity, with current and quick ratios remaining extremely high throughout the period even after some decline from FY2022 levels. Leverage is light and has improved, with debt-to-equity falling to 0.02, indicating a very conservative balance sheet. Efficiency is harder to judge because receivables and inventory turnover are unavailable, but asset turnover at 0.65 suggests only moderate use of assets. The main weakness is profitability: operating, pre-tax, and net margins have fallen sharply into negative territory, and ROE and ROA are also negative in the latest period. Gross margin is still healthy, but overall returns and earnings quality are weak.

Silicon Laboratories shows a clear turnaround pattern: revenue fell from 1.02B USD to 0.58B USD before recovering to 0.78B USD and is projected to climb to 0.93B USD and then 1.08B USD, suggesting steady re-acceleration rather than abrupt growth. The earlier contraction and sharp EPS swing from 2.54 to -5.93 point to a volatile earnings base, but the forecast EPS path back to 2.81 and 4.26 indicates a meaningful rebound with earnings growing faster than revenue, which implies margin recovery. Analyst sentiment is cautious and stable, with a Hold consensus, a tight 200 to 231 target range, and 7 analysts providing moderate confidence. The recommendation mix has remained unchanged across recent months.